Clinical trials
Non-Hodgkin Lymphoma clinical trials
Below are recruiting non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 309 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03571568RecruitingPhase 1/Phase 2
Study of BI-1206 plus rituximab, with or without acalabrutinib
This early-phase study tests BI-1206 combined with rituximab, and possibly adds acalabrutinib, in people with certain slow-growing B-cell lymphomas that have come back or did not respond to prior treatment. The goal is to see whether this treatment approach shrinks lymphoma safely and effectively.
Atlanta, GeorgiaAges 18 years+ - NCT05524298Recruiting
Quality of life study in older adults with low-grade lymphoma
This study looks at quality of life in people age 70 and older with slow-growing (low-grade) B-cell non-Hodgkin lymphoma who haven’t been treated yet. It requires a geriatric (aging-focused) check before starting care, to see what helps older patients feel better during treatment.
Alessandria, AlessandriaAges 70 years+ - NCT04906096RecruitingPhase 2
Paxalisib for repeat or resistant brain lymphoma
This Phase 2 study tests paxalisib to shrink or control primary CNS lymphoma that has come back or did not respond to prior treatment. It may help by blocking specific cell-growth signals that can drive this lymphoma.
Boston, MassachusettsAges 18 years+ - NCT06395870RecruitingPhase 1
Dual-target cell therapy for returning B-cell lymphoma
This trial tests a new cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is for patients whose B-cell non-Hodgkin lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help control the cancer.
Hefei, AnhuiAges 18–75 - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06346912RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell blood cancers
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT05741359RecruitingPhase 1
Study of BRL-201 for hard-to-treat aggressive B-cell lymphoma
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
Wuhan, HubeiAges 18 years+ - NCT07093411RecruitingEarly Phase 1
Targeted cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
HefeiAges 18–75 - NCT06618313Recruiting
Testing JCXH-213 for B-cell lymphoma that returned or didn't respond
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
BeijingAges 18 years+ - NCT06461182RecruitingPhase 2
PET Scan Test for Slow-Growing Lymphoma
This trial uses a special PET scan to take detailed pictures of slow-growing lymphomas, likely before or after your regular treatment scan. It may help your doctor see exactly where the lymphoma is in your body.
Taipei, BeitouAges 20–100 - NCT07168980RecruitingPhase 2/Phase 3
Chemotherapy plus rituximab for aggressive B-cell lymphoma in kids
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Birmingham, AlabamaAges 6 months–30 years - NCT05685173RecruitingPhase 1
Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
Duarte, CaliforniaAges 18 years+ - NCT06835530RecruitingPhase 2
Rituximab and CC-99282 for older frail patients with large b-cell lymphoma
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
AlessandriaAges 80 years+ - NCT07271121RecruitingPhase 2
CAR T cells for CD19+ aggressive lymphoma
This trial tests a personalized treatment where your own immune cells are modified to find and kill lymphoma cells that have a protein called CD19. It may be an option if your lymphoma has returned or not responded to standard treatments.
AmmanAges 18–75 - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT06386315RecruitingPhase 2
Lower dose radiation for slow-growing lymphoma
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
Scottsdale, ArizonaAges 18 years+ - NCT07283796RecruitingPhase 1
Study of HSK47977 for relapsed or refractory non-Hodgkin lymphoma
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
TianjinAges 18 years+ - NCT07059741Recruiting
Radiation, stem cell transplant, and CAR-T for aggressive B-cell lymphoma
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
Suzhou, JiangsuAges 18 years+ - NCT07248163Recruiting
Universal CAR-T cell therapy for non-Hodgkin lymphoma
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
ShanghaiAges 18 years+ - NCT02872987Recruiting
Adult blood cancer registry study with stored samples
This study enrolls adults with certain blood cancers to better understand diagnosis, treatment choices, and outcomes. You may also be asked to provide or have tissue/blood samples saved so researchers can study what’s going on in the disease.
GrazAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Gilbert, ArizonaAges 18 years+ - NCT03011814RecruitingPhase 1/Phase 2
Durvalumab plus lenalidomide for relapsed T-cell lymphoma
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Duarte, CaliforniaAges 18 years+ - NCT01676805Recruiting
Collecting tissue samples for lymphoma research
This study collects leftover tissue samples from patients with or without lymphoma to help researchers better understand lymph system cancers. It may be an option if you are already having a biopsy or surgery.
Bethesda, MarylandAges 18 years+
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-hodgkin lymphoma?
- Yes. Clin2 currently lists 309 recruiting non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.